New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - eptifibatide 2 mg/ml (20 mg in 10 ml) - solution for injection - 2 mg/ml - active: eptifibatide 2 mg/ml (20 mg in 10 ml) excipient: citric acid monohydrate sodium hydroxide water for injection - indicated for patients undergoing non-urgent, percutaneous coronary intervention (pci) with coronary stenting for the reduction of death, myocardial infarction, urgent revascularisation and the need for acute antithrombotic rescue therapy. indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction. indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is intended for use with aspirin, heparin or clopidigrel.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - eptifibatide - solution for infusion - 750microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord healthcare ltd - eptifibatide - solution for injection - 2mg/1ml

Israel - English - Ministry of Health

a.l. medi-market ltd. - eptifibatide - solution for infusion - eptifibatide 0.75 mg / 1 ml - eptifibatide - eptifibatide medi-market is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide medi-market is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide medi-market is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). eptifibatide medi-market is intended for use with aspirin and heparin.

Israel - English - Ministry of Health

a.l. medi-market ltd. - eptifibatide - solution for injection - eptifibatide 2 mg / 1 ml - eptifibatide - eptifibatide medi-market is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide medi-market is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide medi-market is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). eptifibatide medi-market is intended for use with aspirin and heparin.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - solution for infusion - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - solution for injection - eptifibatide 2 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - eptifibatide - solution for infusion - 0.75 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - eptifibatide - solution for injection - 2 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - eptifibatide - solution for infusion - 0.75 mg/ml - platelet aggregation inhibitors excl. heparin